LETROZOLE ACCORD HEALTHCARE 2
Sponsors
F. Hoffmann-La Roche AG, Pfizer Inc.
Conditions
Breast CancerEarly-StageEndocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-MutatedEstrogen Receptor-PositiveHER2-Negative Early Breast CancerHormone Receptor-PositiveMetastatic breast cancerOvarian Cancer
Phase 1
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)
RecruitingCTIS2023-503629-20-00
Start: 2018-06-27Target: 50Updated: 2025-08-14
C4161001: PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Active, not recruitingCTIS2024-515492-34-00
Start: 2023-03-30Target: 12Updated: 2025-11-22
Phase 2
Phase 3
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer
Active, not recruitingCTIS2023-507172-44-00
Start: 2021-09-10Target: 1482Updated: 2025-11-25
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA -Mutated, Hormone Receptor-Positive, HER2- Negative Advanced Breast Cancer
RecruitingCTIS2024-516162-11-00
Start: 2025-07-14Target: 176Updated: 2025-11-10